alpha-MSH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
1960: British primatologist Jane Goodall began studying chimpanzees in Tanzania; her study of them continued for over 50 years. Her observations challenged previous ideas that only humans made tools and that chimpanzees had a basically vegetarian diet. Early 1960s: German-Canadian metallurgist Ursula Franklin studied levels of radioactive isotope strontium-90 that were appearing in the teeth of children as a side effect of nuclear weapons testing fallout. Her research influenced the Partial Nuclear Test Ban Treaty of 1963. 1960s: American mathematician Katherine Johnson calculated flight paths at NASA for crewed space flights. 1961: Indian chemist Asima Chatterjee became the first female recipient of a Shanti Swarup Bhatnagar Prize. She was recognized in the Chemical Sciences category for her contributions to phytomedicine. 1962: Rachel Louise Carson was an American marine biologist, author, and conservationist whose book Silent Spring and other writings are credited with advancing the global environmental movement. 1962: South African botanist Margaret Levyns became the first female president of the Royal Society of South Africa. 1962: French physicist Marguerite Perey became the first female Fellow elected to the Académie des Sciences. 1963: Elsa G. Vilmundardóttir became the first female Icelandic geologist, completing her studies at Stockholm University. 1963: Maria Goeppert Mayer became the first American woman to receive a Nobel Prize in Physics; she shared the prize with J. Hans D.
Evaporated milk, known in some countries as "unsweetened condensed milk", is a shelf-stable canned cow’s milk product, consisting of fresh milk from which approximately 60% of the water has been removed. French inventor Nicolas Appert, the "father of food science", perfected the process in the 1820s. It differs from sweetened condensed milk, which contains added sugar and requires less processing to preserve, as the added sugar inhibits bacterial growth. The production process involves the evaporation of 60% of the water from the milk, followed by homogenization, canning and heat sterilization. Evaporated milk consumes half the space of its nutritional equivalent in fresh milk. When the liquid product is mixed with a proportionate amount of water (150%), evaporated milk becomes the rough equivalent of fresh milk. This allows the product to have a shelf life of months or even years, depending upon the fat and sugar content, which made evaporated milk very popular before the age of refrigeration as a safe and reliable substitute for perishable fresh milk, as it could be shipped easily to locations lacking the means of safe milk production or storage.
=== Low glutathione levels === Kwashiorkor is also marked by low glutathione levels. Glutathione is used in many of the body processes on a molecular level. It is believed to be related to high oxidant levels commonly seen in people who suffer from starvation and rarely in chronic inflammation. Glutathione serves vital functions including management of oxidative stress which is an imbalance that plays a key role in the pathogenesis of many diseases. Evidence indicates that amino acid balance has an important effect on protein nutrition and therefore on glutathione homeostasis. Cysteine is an essential amino acid that acts as the limiting amino acid for glutathione synthesis in humans. Factors that increase demand for glutathione may increase demand for cysteine, and hence methionine. Such demands have been hypothesized to increase the risk for kwashiorkor.
Sources: en.wikipedia.org
Other azo dyes, which were previously used in textiles, printing, and plastic manufacturing, have been implicated as carcinogens that can cause bladder cancer. While phenazopyridine has never been shown to cause cancer in humans, evidence from animal models suggests that it is potentially carcinogenic.
=== Chemical === Copernicium is the tenth and last member of the 6d series and is the heaviest group 12 element in the periodic table, below zinc, cadmium and mercury. It is predicted to differ significantly from the lighter group 12 elements. The valence s-subshells of the group 12 elements and period 7 elements are expected to be relativistically contracted most strongly at copernicium. This and the closed-shell configuration of copernicium result in it probably being a very noble metal. A standard reduction potential of +2.1 V is predicted for the Cn2+/Cn couple. Copernicium's predicted first ionization energy of 1155 kJ/mol almost matches that of the noble gas xenon at 1170.4 kJ/mol. Copernicium's metallic bonds should also be very weak, possibly making it extremely volatile like the noble gases, and potentially making it gaseous at room temperature. However, it should be able to form metal–metal bonds with copper, palladium, platinum, silver, and gold; these bonds are predicted to be only about 15–20 kJ/mol weaker than the analogous bonds with mercury. In opposition to the earlier suggestion, ab initio calculations at the high level of accuracy predicted that the chemistry of singly-valent copernicium resembles that of mercury rather than that of the noble gases. The latter result can be explained by the huge spin–orbit interaction which significantly lowers the energy of the vacant 7p1/2 state of copernicium. Once copernicium is ionized, its chemistry may present several differences from those of zinc, cadmium, and mercury.
The raised square bar and multilevel dining became the company standard. Dallas doubled the sales and tripled profits of TGI Fridays' previous best. Families began visiting the new suburban locations during the day for casual food; "it took six or seven years, but T.G.I. Fridays became a very different animal", Stillman said. Attracted by this performance, he merged into the Dallas franchise, forming TGI Fridays, Inc., and Scoggin was the CEO for the next 15 years. Scoggin is credited with the then-new 200-seat prototype and many of the TGI Fridays innovations including a large from-scratch menu, potato skins, bartender Olympics, and frozen drinks. In 1975, the company was sold to Carlson Companies, and Stillman and the original investors departed. Stillman kept the original location and, now married, founded Smith & Wollensky in 1977 with Benson. Scoggin continued as CEO on an earn-out contract and finalized his sale in 1980, signing a new contract to continue as the company's CEO. When the company was passing through the 100-store mark, it issued an initial public offering in 1983 with Goldman Sachs. Scoggin developed the first international franchise and the template for future international development. The first restaurant was opened in the UK with Whitbread PLC. By the time Scoggin departed in 1986, the company had widened its appeal: alcohol consumption was de-emphasized, and quality was emphasized over quantity. The company became privately held again in 1989. The focus was then switched from singles to families.
The International Brain Initiative was created in 2017, currently integrated by more than seven national-level brain research initiatives (US, Europe, Allen Institute, Japan, China, Australia, Canada, Korea, and Israel) spanning four continents.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.